Idiopathic myelofibrosis in children: primary myelofibrosis, essential thrombocythemia, or transient process?

Area of Science:

• Hematology
• Pediatric Oncology
• Oncogenesis

Background:

• Primary/idiopathic myelofibrosis (PMF/IMF) is a rare myeloproliferative neoplasm, predominantly diagnosed in adults.
• Pediatric cases of PMF/IMF are exceptionally uncommon, presenting unique clinical challenges.
• Understanding the distinct behavior of PMF/IMF in children is essential for appropriate management.

Observation:

• Three pediatric cases of PMF/IMF were analyzed, revealing atypical clinical courses compared to adult presentations.
• One case demonstrated spontaneous resolution of both clinical symptoms and bone marrow fibrosis.
• Another case achieved significant myelofibrosis regression with cytoreductive therapy alone.

Findings:

• The third pediatric case, diagnosed with essential thrombocythemia and a JAK2V617F mutation, experienced central venous thrombosis leading to irreversible blindness.
• Pediatric PMF/IMF may carry a lower risk profile than in adults, potentially allowing for less aggressive therapeutic strategies.
• Delayed diagnosis of mutation-positive PMF or essential thrombocythemia in children can result in severe, life-altering consequences.

Implications:

• The findings suggest that risk stratification and management protocols for pediatric PMF/IMF may need to be distinct from those used in adult populations.
• Highlighting the critical need for timely diagnosis and genetic testing (e.g., JAK2V617F) in pediatric patients presenting with myeloproliferative disorders.
• This study underscores the importance of further research into the pathogenesis and long-term outcomes of PMF/IMF in pediatric patients to refine diagnostic and therapeutic approaches.